Gender | Age | Life Expectancy
Item
men aged ≥40 years and life expectancy of ≥10 years.
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0023671 (UMLS CUI [3])
Prostate specific antigen measurement
Item
serum prostate-specific antigen (psa) ≤15 ng/ml.
boolean
C0201544 (UMLS CUI [1])
Transperineal biopsy of prostate | Lesion Clinical Significance | Correlation Lesion Visible mp-MRI
Item
transperineal prostate biopsy within 12 months prior to dosing, with a clinically significant lesion correlating with an mpmri visible lesion.
boolean
C0401642 (UMLS CUI [1])
C0221198 (UMLS CUI [2,1])
C2826293 (UMLS CUI [2,2])
C1707520 (UMLS CUI [3,1])
C0221198 (UMLS CUI [3,2])
C0205379 (UMLS CUI [3,3])
C3898221 (UMLS CUI [3,4])
Disease TNM clinical staging
Item
radiological stage t1-t2 n0 mx/m0 disease.
boolean
C0012634 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
Lesion Visible mp-MRI | Access PRX302 Injection transperineal
Item
a visible lesion on mpmri that is accessible to prx302 transperineal injection.
boolean
C0221198 (UMLS CUI [1,1])
C0205379 (UMLS CUI [1,2])
C3898221 (UMLS CUI [1,3])
C0444454 (UMLS CUI [2,1])
C1831975 (UMLS CUI [2,2])
C1828121 (UMLS CUI [2,3])
C0205500 (UMLS CUI [2,4])
Radiotherapy to pelvis
Item
previous radiation therapy to the pelvis.
boolean
C1536155 (UMLS CUI [1])
Androgen suppression Prostate carcinoma | Antiandrogen therapy Prostate carcinoma
Item
androgen suppression or anti-androgen therapy within the 12 months prior to dosing, for prostate cancer.
boolean
C1515985 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
C0279492 (UMLS CUI [2,1])
C0600139 (UMLS CUI [2,2])
5-alpha Reductase Inhibitors
Item
use of a 5-alpha reductase inhibitor within the 3 months prior to dosing.
boolean
C2936788 (UMLS CUI [1])
Neoplasm Metastasis Extraprostatic Bone scan | Disorder of lymph node Extraprostatic Bone scan | Neoplasm Metastasis Extraprostatic Cross-sectional imaging | Disorder of lymph node Extraprostatic Cross-sectional imaging
Item
evidence of metastatic disease or nodal disease outside the prostate on bone scan or cross-sectional imaging.
boolean
C0027627 (UMLS CUI [1,1])
C1517078 (UMLS CUI [1,2])
C0203668 (UMLS CUI [1,3])
C0272394 (UMLS CUI [2,1])
C1517078 (UMLS CUI [2,2])
C0203668 (UMLS CUI [2,3])
C0027627 (UMLS CUI [3,1])
C1517078 (UMLS CUI [3,2])
C3824793 (UMLS CUI [3,3])
C0272394 (UMLS CUI [4,1])
C1517078 (UMLS CUI [4,2])
C3824793 (UMLS CUI [4,3])
Transrectal ultrasound Receive Unable
Item
inability to tolerate a transrectal ultrasound (trus).
boolean
C0373345 (UMLS CUI [1,1])
C1514756 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])
Latex allergy | Hypersensitivity Gadolinium
Item
known allergy to latex or gadolinium (gd).
boolean
C0577628 (UMLS CUI [1])
C0020517 (UMLS CUI [2,1])
C0016911 (UMLS CUI [2,2])
Electroporation Prostate carcinoma | Radiofrequency ablation Prostate carcinoma | High intensity focused ultrasound Prostate carcinoma | Cryosurgery Prostate carcinoma | Thermal therapy Prostate carcinoma | Microwave Therapy Prostate carcinoma
Item
previous electroporation, radiofrequency ablation, high-intensity focused ultrasound (hifu), cryosurgery, thermal or microwave therapy to treat cancer of the prostate.
boolean
C0206691 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
C0850292 (UMLS CUI [2,1])
C0600139 (UMLS CUI [2,2])
C0441583 (UMLS CUI [3,1])
C0600139 (UMLS CUI [3,2])
C0010408 (UMLS CUI [4,1])
C0600139 (UMLS CUI [4,2])
C0454527 (UMLS CUI [5,1])
C0600139 (UMLS CUI [5,2])
C0438673 (UMLS CUI [6,1])
C0600139 (UMLS CUI [6,2])
MRI of Pelvis Receive Unable | Claustrophobia Severe | Permanent pacemaker | Metallic implant
Item
unable to have pelvic mri scanning (severe claustrophobia, permanent cardiac pacemaker, metallic implant, etc. likely to contribute significant artifact to images).
boolean
C0203201 (UMLS CUI [1,1])
C1514756 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])
C0008909 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0281945 (UMLS CUI [3])
C3693688 (UMLS CUI [4])